Healthy longevity is one of the main development goals of ANEW’s novel gene therapy Page 1

Company to use new, patented Klotho gene (s-KL) in studies

NEW YORK, Sept. 4, 2024 (GLOBE NEWSWIRE) — ANEW MEDICAL, INC. (NASDAQ: WENA), an American biotechnology company, announced that it has two clear goals for its groundbreaking development of cell and gene therapies. One is to enhance people’s potential to achieve healthy longevity, and the other is to develop effective treatments for age-related conditions and neurodegenerative diseases such as ALS, Alzheimer’s and Parkinson’s.

ANEW has secured exclusive worldwide rights and issued patents in the U.S., Canada, Europe, Hong Kong and China covering the secreted form of Klotho, scientifically known as s-KL. Klotho is often referred to as “the anti-aging gene.” It is named after the Greek goddess who is said to spin the thread of life.